When utilized for managing weight, Semaglutide may be continued as long as it’s proving effective and is not producing any adverse or unwanted side effects.

Due to data from rodents studies of GLP-1-mediated thyroid C-cell hyperplasia, the use of Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2.

You are going to give yourself a little injection under the skin (with the same small needle that you get your neurotoxin with) once a week.

Semaglutide is associated with GI adverse reactions, including nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, abdominal distention, eructation, flatulence, gastroenteritis, and gastroesophageal reflux disease. It has also been associated with causing headache, fatigue, dizziness, and hypoglycemia in patients with type 2 diabetes. Please discuss with your physician the contraindications and other warning and precautions before starting Semaglutide.

It depends. Semaglutide helps the insulin in your body work much more effectively while you are on the medication. If you stop the medication shortly after starting it, you will see very little change. If you’ve been on Semaglutide long term and then stop taking it, the lifestyle component becomes crucial. If you’ve developed and habituated healthy lifestyle habits, you will likely succeed at keeping the weight off. This includes ensuring you eat a healthy, nutritious diet that is appropriate for your weight maintenance goals, exercising regularly, and getting enough refreshing sleep on a nightly basis.

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist that belongs to a class of drugs called incretin mimetics. Incretins are a type of hormone that stimulate a decrease in blood glucose levels, such as GLP-1 that binds to and activates the GLP-1 receptor. GLP-1 works to regulate ones appetite and caloric intake, and the GLP-1 receptor is present in several areas of your body, including areas in your brain responsible for appetite regulation. Semaglutide, as an agonist, binds to the GLP-1 receptor and works to lower blood glucose by stimulating insulin secretion and to inhibit glucagon release.